Better CNS Control in Children With ALL:'Goldilocks' Approach Better CNS Control in Children With ALL:'Goldilocks' Approach
Treatment of central nervous system involvement in pediatric acute lymphoblastic leukemia needs to be based on risk, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Duration of Maintenance Therapy Studied in Childhood ALL
MONDAY, Aug. 2, 2021 -- For patients with low-risk childhood acute lymphoblastic leukemia, the omission of seven pulses of therapy with vincristine and oral dexamethasone during the second year of maintenance therapy might not worsen treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 2, 2021 Category: Pharmaceuticals Source Type: news
Inotuzumab ozogamicin cost effective for acute lymphoblastic leukaemia in Sweden and Norway
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news
FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news
Incidence Rates of Pediatric Cancers Vary by Race, Ethnicity
Variation seen by single year of age, including lower incidence of acute lymphoblastic leukemia in Blacks, especially at 1 to 7, 16 to 20 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 21, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Journal, Source Type: news
Venetoclax Shows Activity Against T-ALL in Children Venetoclax Shows Activity Against T-ALL in Children
Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia in children and young adults.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Combination therapy achieves high rates of response for patients with ALL
(University of Texas M. D. Anderson Cancer Center) A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news
Philip Schofield hails 'big step forward' cancer treatment that's saving lives
A GAME-CHANGING treatment for acute lymphoblastic leukaemia - a rare cancer of the blood cells - has been discovered. Philip Schofield remarked on the findings on ITV's This Morning on Monday. (Source: Daily Express - Health)
Source: Daily Express - Health - May 4, 2021 Category: Consumer Health News Source Type: news
Using personalized medicine to avoid resistance to leukemia treatment
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years. (Source: World Pharma News)
Source: World Pharma News - May 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Using personalized medicine to avoid resistance to leukemia treatment
(University of Copenhagen - The Faculty of Health and Medical Sciences) T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this. Now, researchers from the University of Copenhagen have found a combination treatment that could benefit these patients and increase the survival rate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news
Healthcare use and costs for childhood acute lymphoblastic leukaemia differ by treatment protocol in Ontario, Canada
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news
Steroids Unrelated to Psychological Reactions in Pediatric ALL
MONDAY, April 26, 2021 -- For children with acute lymphoblastic leukemia (ALL), the type/dose of steroid seems not to be related to adverse psychological reactions (APRs) but may be associated with sleep problems, according to a review published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2021 Category: Pharmaceuticals Source Type: news
'Information theory' recruited to help scientists find cancer genes
(Johns Hopkins Medicine) Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2021 Category: Cancer & Oncology Source Type: news
Diet, Exercise Intervention Explored in Children With B-ALL
THURSDAY, April 8, 2021 -- For children with B-cell acute lymphoblastic leukemia (B-ALL), a diet and exercise intervention might improve disease response, according to a study published online April 1 in Blood Advances.
Etan Orgel, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news
